{
    "clinical_study": {
        "@rank": "31788", 
        "acronym": "PP-01", 
        "arm_group": [
            {
                "arm_group_label": "Iron isomaltoside 1000 (Monofer\u00ae)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Standard medical Care", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to compare the efficacy of IV high single dose infusion\n      of iron isomaltoside 1000 to standard medical care in women with PPH evaluated as physical\n      fatigue."
        }, 
        "brief_title": "Treatment of Women After Postpartum Haemorrhage", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Postpartum Haemorrhage", 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Postpartum Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Women with PPH \u2265 700 and \u2264 1000 mL or PPH > 1000 mL and Hb > 6.5 g/dL (4.0 mmol/L)\n             measured > 12 hours after delivery\n\n          2. Willingness to participate and signed the informed consent form\n\n        Exclusion Criteria:\n\n          1. Women aged < 18 years\n\n          2. Multiple births\n\n          3. Peripartum RBC transfusion\n\n          4. Known iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and\n             haemosiderosis)\n\n          5. Known hypersensitivity to parenteral iron or any excipients in the investigational\n             drug products\n\n          6. Women with a history of active asthma within the last 5 years or a history of\n             multiple allergies\n\n          7. Known decompensated liver cirrhosis and active hepatitis\n\n          8. Women with HELLP (Haemolysis Elevated Liver enzymes Low Platelet count) syndrome\n             (defined according to \"Dansk Selskab for Obstetrik og Gyn\u00e6kologi guidelines\")\n\n          9. Active acute infection assessed by clinical judgement\n\n         10. Rheumatoid arthritis with symptoms or signs of active joint inflammation\n\n         11. History of anaemia caused by e. g. thalassemia, hypersplenism or haemolytic anaemia\n             (known haematologic disorder other than iron deficiency)\n\n         12. Not able to read, speak and understand the Danish language\n\n         13. Participation in any other clinical study where the study drug has not passed 5\n             half-lives prior to the baseline\n\n         14. Any other medical condition that, in the opinion of the Investigator, may cause the\n             patient to be unsuitable for completion of the study or place the patient at\n             potential risk from being in the study. For example, a malignancy, uncontrolled\n             hypertension, unstable ischaemic heart disease or uncontrolled diabetes mellitus"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01895218", 
            "org_study_id": "PP-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Iron isomaltoside 1000 (Monofer\u00ae)", 
                "description": "A single dose of 1200 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9 % sodium chloride and given over approximately 15 min.", 
                "intervention_name": "Iron isomaltoside 1000", 
                "intervention_type": "Drug", 
                "other_name": "Monofer\u00ae"
            }, 
            {
                "arm_group_label": "Standard medical Care", 
                "description": "Standard medical Care is most often to recommend women with PPH to continue oral iron supplementation as recommended during pregnancy or to advise the subject to take 100 mg oral iron 1-2 times a day", 
                "intervention_name": "Standard medical Care", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Iron", 
                "Ferric Compounds"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Copenhagen", 
                    "country": "Denmark"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "A, Randomized Comparative, Open-Label Study of Intravenous Iron Isomaltoside 1000 (Monofer\u00ae) Administered by High Single Dose In-fusions or Standard Medical Care in Women After Postpartum Haemorrhage", 
        "other_outcome": [
            {
                "measure": "Change in anaemia symptoms", 
                "safety_issue": "Yes", 
                "time_frame": "From exposure to day 3, week 1, 3, 8 and 12 post-exposure"
            }, 
            {
                "measure": "Change in gastrointestinal symptoms", 
                "safety_issue": "Yes", 
                "time_frame": "From exposure to day 3, week 1, 3, 8 and 12 post-exposure"
            }
        ], 
        "overall_contact": {
            "email": "LLT@Pharmacosmos.com", 
            "last_name": "Lars Lykke Thomsen", 
            "phone": "+45 59 48 59 59"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Danish Health and Medicines Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this study is to compare efficacy of IV high single dose infusion of iron isomaltoside 1000 to standard medical care in women with PPH evaluated as physical fatigue.", 
            "measure": "Physical fatigue", 
            "safety_issue": "No", 
            "time_frame": "From exposure to 12 weeks post-exposure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01895218"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in Hb concentration", 
                "safety_issue": "No", 
                "time_frame": "From exposure to week 1, 3, 8 and 12 post-exposure"
            }, 
            {
                "measure": "Change in concentrations of p-ferritin", 
                "safety_issue": "No", 
                "time_frame": "From exposure to day 3, week 1, 3, 8 and 12 post-exposure"
            }, 
            {
                "measure": "Change in Fatigue symptoms", 
                "safety_issue": "No", 
                "time_frame": "From exposure to day 3, week 1, 3, 8 and 12 post-exposure"
            }, 
            {
                "measure": "Change in postpartum depression symptoms", 
                "safety_issue": "No", 
                "time_frame": "From exposure to 12 weeks post-exposure"
            }, 
            {
                "measure": "Breastfeeding", 
                "safety_issue": "No", 
                "time_frame": "From exposure to 12 weeks post-exposure"
            }, 
            {
                "measure": "RCB transfusions", 
                "safety_issue": "No", 
                "time_frame": "From exposure to 12 weeks post-exposure"
            }, 
            {
                "measure": "Adverse drug reactions (ADRs)", 
                "safety_issue": "Yes", 
                "time_frame": "From exposure to day 3, week 1, 3, 8 and 12 post-exposure"
            }, 
            {
                "measure": "Change in concentrations of p-iron", 
                "safety_issue": "No", 
                "time_frame": "From exposure to day 3, week 1, 3, 8 and 12 post-exposure"
            }, 
            {
                "measure": "Change in concentrations of p-transferrin", 
                "safety_issue": "No", 
                "time_frame": "From exposure to day 3, week 1, 3, 8 and 12 post-exposure"
            }, 
            {
                "measure": "Change in concentrations of transferrin saturation (TSAT)", 
                "safety_issue": "No", 
                "time_frame": "From exposure to day 3, week 1, 3, 8 and 12 post-exposure"
            }, 
            {
                "measure": "Change in concentrations of reticulocyte count", 
                "safety_issue": "No", 
                "time_frame": "From exposure to day 3, week 1, 3, 8 and 12 post-exposure"
            }, 
            {
                "measure": "Change in concentrations of mean reticulocyte haemoglobin content (CHr)", 
                "safety_issue": "No", 
                "time_frame": "From exposure to day 3, week 1, 3, 8 and 12 post-exposure"
            }, 
            {
                "measure": "Change in haematology parameters", 
                "safety_issue": "Yes", 
                "time_frame": "From exposure to day 3, week 1, 3, 8 and 12 post-exposure"
            }
        ], 
        "source": "Pharmacosmos A/S", 
        "sponsors": {
            "collaborator": {
                "agency": "BioStata", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Pharmacosmos A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}